Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
First Claim
Patent Images
1. An imaging compound comprising:
- a thyroid hormone analog, wherein the thyroid hormone analog is covalently bonded to a linker selected from the group consisting of diaminopropane, ether, sulfhydryl, ester and anhydride linkages, and the linker is covalently bonded to a radio-labelled tracer selected from the group consisting of iodine-123 (123I), iodine-124 (124I), iodine-125 (125I), iodine-131 (131I), fluorine-18 (18F), technetium-99m (99mTc), indium-111 (111In), carbon-11 (11C) and astatine-210 (210At), wherein the imaging compound is a nanoparticle.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
99 Citations
13 Claims
-
1. An imaging compound comprising:
a thyroid hormone analog, wherein the thyroid hormone analog is covalently bonded to a linker selected from the group consisting of diaminopropane, ether, sulfhydryl, ester and anhydride linkages, and the linker is covalently bonded to a radio-labelled tracer selected from the group consisting of iodine-123 (123I), iodine-124 (124I), iodine-125 (125I), iodine-131 (131I), fluorine-18 (18F), technetium-99m (99mTc), indium-111 (111In), carbon-11 (11C) and astatine-210 (210At), wherein the imaging compound is a nanoparticle. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
Specification